<DOC>
	<DOCNO>NCT02066909</DOCNO>
	<brief_summary>This study design evaluate safety plasma concentration PF-06649751 healthy volunteer follow one two time daily oral dose PF-06649751 14 day ( Cohorts 1 - 4 ) , 21 day ( Cohort 5 ) , 28 day ( Cohorts 6 - 8 ) . Cohort 9 dose Japanese healthy volunteer manner identical Cohort 4 intend bridge safety/tolerability PK data Western Japanese population .</brief_summary>
	<brief_title>A Study To Observe Safety And Blood Concentrations Of PF-06649751 During And Following The Oral Administration Of Multiple Doses Of PF-06649751 In Healthy Adult Western Japanese Volunteers</brief_title>
	<detailed_description />
	<criteria>Healthy male and/or female subject non childbearing potential age 18 55 year , inclusive ( healthy define clinically relevant abnormality identify detailed medical history , full physical examination , include blood pressure pulse rate measurement , 12 lead ECG clinical laboratory test ) . Body Mass Index ( BMI ) 17.5 30.5 kg/m2 ; total body weight &gt; 50 kg ( 110 lb ) . Cohort 9 : Japanese subject must four biologic Japanese grandparent born Japan . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) . Other severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation investigational product administration may interfere interpretation study result , judgment investigator , would make subject inappropriate entry study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>pharmacokinetics</keyword>
	<keyword>safety</keyword>
	<keyword>tolerability</keyword>
	<keyword>healthy volunteer</keyword>
	<keyword>steady state</keyword>
	<keyword>multiple dos</keyword>
	<keyword>Japanese subject</keyword>
</DOC>